1. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement. 2010; 6:98–103.
Article
2. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010; 9:702–716.
Article
3. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008; 3:211–225.
4. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science. 2006; 314:781–784.
Article
5. Maggini M, Vanacore N, Raschetti R. Cholinesterase inhibitors: drugs looking for a disease? PLoS Med. 2006; 3:e140.
Article
6. Lindvall O, Hyun I. Medical innovation versus stem cell tourism. Science. 2009; 324:1664–1665.
Article
7. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009; 6:e1000029.
Article
8. Pontes-Neto OM, Silva GS, Feitosa MR, de Figueiredo NL, Fiorot JA Jr, Rocha TN, et al. Stroke awareness in Brazil: alarming results in a community-based study. Stroke. 2008; 39:292–296.
9. Enserink M. Biomedicine. Selling the stem cell dream. Science. 2006; 313:160–163.
10. Gaskell G, Einsiedel E, Hallman W, Priest SH, Jackson J, Olsthoorn J. Communication. Social values and the governance of science. Science. 2005; 310:1908–1909.
11. Ryan KA, Sanders AN, Wang DD, Levine AD. Tracking the rise of stem cell tourism. Regen Med. 2010; 5:27–33.
Article
12. Shineha R, Kawakami M, Kawakami K, Nagata M, Tada T, Kato K. Familiarity and prudence of the Japanese public with research into induced pluripotent stem cells, and their desire for its proper regulation. Stem Cell Rev. 2010; 6:1–7.
Article
13. Einsiedel E, Premji S, Geransar R, Orton NC, Thavaratnam T, Bennett LK. Diversity in public views toward stem cell sources and policies. Stem Cell Rev. 2009; 5:102–107.
Article
14. Kim YS, Chung DI, Choi H, Baek W, Kim HY, Heo SH, et al. Fantasies about stem cell therapy in chronic ischemic stroke patients. Stem Cells Dev. 2013; 22:31–36.
Article
15. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc. 1997; 15:300–308.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412–2414.
17. Chen WW, Blurton-Jones M. Concise review: can stem cells be used to treat or model Alzheimer’s disease? Stem Cells. 2012; 30:2612–2618.
Article
18. Dantuma E, Merchant S, Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther. 2010; 1:37.
Article
19. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010; 28:1099–1106.
Article
20. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011; 134(Pt 6):1790–1807.
Article
21. Zarzeczny A, Caulfield T. Stem cell tourism and doctors’ duties to minors--a view from Canada. Am J Bioeth. 2010; 10:3–15.
Article
22. Regenberg AC, Hutchinson LA, Schanker B, Mathews DJ. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells. 2009; 27:2312–2319.
Article